Stone Pharmaceutical Innovation (300765.SZ) subsidiary SYS6010 initiates Phase III clinical trial.

News from the Wise Finance & Economics App, Sihuan Pharmaceutical Innovation (300765.SZ) announced that its controlling subsidiary, Sihuan Group Dide Stone Biopharmaceutical Co., Ltd. (referred to as "Dide Stone Biopharmaceutical"), has recently initiated a randomized, open-label, multicenter, Phase III clinical trial of SYS6010 in combination with Enro and Sobic monoantigen for first-line treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) with negative drive gene and positive PD-L1 expression.